Men in a VA rehabilitation unit who had osteoporosis were older and thinner, but otherwise similar (metabolic and functional status) to control subjects.
To evaluate the prevalence of previously unrecognized osteoporosis in men admitted for long-term rehabilitation nursing home care.
A total of 1179 consecutive admissions to a VA rehabilitation center were reviewed. Men who were already diagnosed with osteoporosis, had confounding medical illness, were unable to complete the study, or who declined to participate were excluded. A total of 153 patients were enrolled and 106 were evaluated. Measurements included dual-energy X-ray absorptiometry of the hip and lumbar spine, biochemical and hormonal studies, and functional evaluation.
A total of 33 patients (31.1%) had osteoporosis (T-score at any site lumbar spine, total hip, or femoral neck <−2.5). Patients with osteoporosis were significantly older than those without: 68.4 ± 13.2 years versus 62.7 ± 12.1 years (P <.05), respectively. Body mass index (BMI) and weight were lower in men with osteoporosis: 23.4 ± 3.9 kg/m2 versus 28.7 ± 7.08 kg/m2 and 72.6 ± 14.4 kg versus 90.3 ± 23.8 kg, respectively (both, P <.001). There were no differences in use of medications thought to affect bone metabolism or functional status, or in hormonal and metabolic measurements. Hip and spine bone density were correlated (r = 0.3, P <.05). Multivariate analysis showed that hip bone density was independently associated with BMI.
Hip osteoporosis is common in this unscreened population, suggesting that screening should be more widely performed in veterans admitted to rehabilitation units. These data suggest that nutritional status could impact osteoporosis risk.
(Am J Manag Care. 2010;16(6):427-433)
The prevalence of previously unrecognized osteoporosis in men admitted for long-term rehabilitation nursing home care was evaluated in a cross-sectional study.
Osteoporosis is a significant health problem in the United States, and its impact is growing as the population ages. The annual financial burden from osteoporosis has been estimated at $13.9 billion (in 1995), primarily reflecting the cost of hip fracture, surgical repair, nursing home stays, and rehabilitation.1 A similar impact has been reported in other industrialized countries such as Belgium,2 and this impact will be felt throughout the world.3,4 To date, most of the studies on osteoporosis have focused on women, but it is increasingly apparent that men are affected as well. Estimates of osteoporosis in men have varied, but available data suggest that up to 30% of elderly (age >65 years) men will have an osteoporotic fracture in their lifetime.5-9 Available data on osteoporosis in nursing home patients are sparse, especially in men, but published estimates of prevalence of subnormal bone density range between 40% and 60%.10,11 Given that many high-risk patients (eg, patients on chronic glucocorticoids12-14 or those with chronic liver disease15-18) are not being screened in a systematic manner, available screening and treatment data may underestimate the total prevalence of osteoporosis in our population.
Nursing home patients are at significant risk from osteoporosis and its sequelae, due in part to immobility, concurrent medical problems, poor nutrition, and especially the risk of falls.19,20 The potential benefits of exercise and hip pads to reduce the risk of hip fracture have been studied.21,22 We evaluated the prevalence of osteoporosis in a high-risk population: the largely male, elderly veteran population at the Center for Rehabilitation and Extended Care (CREC) of the VA Northern California Health Care System. In addition, we estimated factors that may contribute to metabolic bone disease.
The CREC currently houses up to 120 patients on 3 wards. These patients are mostly male and elderly. Since January 1999, we have been using an on-site dual-energy x-ray absorptiometry (DEXA) machine to evaluate both trabecular and cortical bone density in the lumbar spine and hip.
Consecutive male patients admitted to the CREC were recruited for the study. We excluded “short-stay” individuals (eg, those recovering from procedures and admitted for <23 hours). We also excluded patients admitted for respite care, those with an inability to cooperate because of dementia or other conditions, those with cancer metastatic to bone or known metabolic bone disease, and patients previously evaluated, diagnosed, or treated for osteoporosis. We obtained approval to approach the patients from providers caring for them; this step also gave us an opportunity to confirm, for example, exclusion for dementia. Patients also were approached in person; if they were off the ward for a home visit, physical therapy, and so forth, they might have been excluded. Written informed consent was obtained from each patient or his legal guardian. The study was approved by the Human Studies Subcommittee of the VA Northern California Health Care System.
Screening for Osteoporosis
Screening was performed by DEXA, using an on-site Lunar XRC-1 (GE-Lunar, Madison, WI), which results in modest radiation exposure and allows serial measurements and evaluation of therapy.23-25 This instrument has a precision of 2% to 3% on repeated measurements of bone density. Osteoporosis was defined by World Health Organization criteria using T-scores of -2.5 or greater at either the lumbar spine, total hip, or the femoral neck. Bone density data were stratified by race-specific criteria in the Lunar database, in keeping with station policy.
Laboratory evaluation of osteoporosis26-39 included overall nutritional health estimated by complete blood count (providing data on white blood cell count and hematocrit) and routine chemistries, including albumin and 25-hydroxy vitamin D. To estimate calcium absorption, 24-hour urinary calcium was used. The prostate-specific antigen and serum protein electrophoresis tests were used to estimate the possibility of occult malignancy contributing to poor bone density. Bone turnover was estimated by total alkaline phosphatase. Bone-active hormones were estimated by measurement of testosterone, parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), and free thyroxine (to assess the thyroid axis40).
Because of the variable and occasionally prolonged in-facility residence, laboratory data closest to the DEXA scan were selected if an analyte was measured more than once. Assayed but undetectable prostate-specific antigen was entered as “0” in the analysis. Parathyroid hormone that was assayed but not detected was entered as one-half the lower limit of detection in the analysis.
Overall health was estimated in part by documenting active medical problems. We also calculated functional status both through case mix index (CMI) and activities of daily living (ADL) scores through the minimum data set package.41
Data are expressed as mean ± SD. The t test was used to compare continuous characteristics of the populations diagnosed with and without osteoporosis. The χ2 test was used to compare discontinuous variables such as ethnicity and use of bone-active medications such as phenytoin, barbiturates, and systemic glucocorticoids. Multivariate analysis using multiple linear regression (SigmaStat version 3.0; Systat Software, Inc, Point Richmond, CA) was used to identify predictors of bone density from variables including age, comorbidity (number of active diagnoses, functional status), nutrition (albumin, hematocrit, white blood cell count, vitamin D, and urinary calcium), and bone-active hormones (testosterone, PTH, TSH, and thyroxine). These variables were adapted from widely accepted causes of secondary osteoporosis in adults.42 P <.05 was considered significant.43 The sponsor had no role in the collection of data, its analysis or interpretation, or approval of the manuscript.
Between July 2000 and April 2006, 1179 consecutive admissions of men were reviewed. A total of 116 patients (9.84%) had already been screened or were receiving therapy for osteoporosis. Of the remaining 1063, 113 men (10.6%) were considered to be too demented on initial chart review to participate, 93 (8.7%) had cancer metastatic to bone or were receiving end-of-life care, and 17 (1.6%) died or were discharged prior to the study. The providers for all other patients were contacted to ascertain whether they were capable of participating. A total of 687 men were approached and either declined to participate, participation was discouraged by their provider, or participation was impractical for logistical reasons during the patient’s inpatient stay. Of the remainder, 153 patients met study criteria and gave written consent; 106 completed the studies. A total of 33 men (31.1%) were diagnosed with osteoporosis in any site; 26 had hip only, 4 both hip and spine, and 2 had spine only. One man had osteoporosis at Ward’s triangle only, but he was not included in the analysis. A total of 42 men had osteopenia (T-scores of −1 to −2.5 at lumbar spine or hip sites), 32 men had no evidence of osteoporosis or osteopenia, and 46 men enrolled in but did not complete the study, usually because of being discharged from the facility prior to completion. Of the 106 men who completed the study, 66 (62.3%) were self-described as white, 33 (31.1%) as African American, 6 (5.7%) as Hispanic, and 1 (0.9%) as Asian. This proportion is similar to the veteran population in our catchment area.
The study was suspended in May 2002 due to a suspension of the facility Federalwide Assurance (FWA); with the restoration of the FWA, the study recommenced in spring 2003. This hiatus allowed us to estimate changes in practice patterns in osteoporosis screening. Prehiatus, 42 of 565 admitted patients (7.43%) had been screened or were treated; posthiatus, 74 of 614 patients (12%) had been screened or were treated. This difference in rates was statistically significant by the χ2 test.
Results comparing men with and without osteoporosis are shown in the . The men with osteoporosis were slightly, but significantly, older than those without osteoporosis. Other clinical markers, including 24-hour urinary calcium, PTH, and alkaline phosphatase, were similar in men with and without osteoporosis. Both groups had low-normal 25-hydroxy vitamin D and low urinary calcium. Thyroidstimulating hormone was slightly but not significantly lower in men with osteoporosis compared with men without osteoporosis, although generally in the normal range. Weight and body mass index (BMI) were both significantly lower in men with osteoporosis than in those without.
Comorbidity—as manifested by length of stay, number of active diagnoses on the problem list, ADL scores, and CMI scores—was comparable between the 2 groups. The number of men receiving medications thought to have bone activity, specifically barbiturate, phenytoin, and systemic glucocorticoids, was too small to calculate significant differences between the groups of men with and without osteoporosis. (Among men identified with osteoporosis, 1 man was on phenobarbital and 1 man was on ongoing glucocorticoids; none were on Dilantin. Among men without osteoporosis, none were taking phenobarbital or Dilantin, and 4 were taking glucocorticoids.) The men who enrolled in but did not complete the study were not significantly different from those with osteoporosis (data not shown) in terms of age and indices of comorbidity. The data were too incomplete otherwise to permit a more thorough comparison.
Because only 153 of 840 men who were eligible and approached for the study agreed to participate, we were concerned that this sample be representative of the CREC population over the time frame of the study. Thus, we reviewed the roster of men deemed eligible for the study and identified a sample: All those whose Social Security number ended in “7” had their data reviewed (number chosen by a random number generator). This “unstudied” group (n = 63) had a self-described ethnic distribution similar to that of the study population. The “unstudied” group was slightly, but significantly, older (70.5 ± 11.7 years vs 64.5 ± 12.7 years; P <.01), but otherwise was similar in terms of active diagnoses, functional status, weight, and BMI.
There was no difference in ethnic composition between men with and without osteoporosis by the χ2 test. Multiple linear regression analysis showed that the significant predictors of hip bone density were lumbar spine bone density (P <.05) and BMI (P <.001). Although lumbar spine bone density predicted hip density, very few men had overt osteoporosis of the spine. Because degenerative changes in the spine can contribute to spuriously high bone density readings, we evaluated our osteoporosis patients for spine degeneration. Lumbar DEXA readings were reviewed, and any patient who was described as having scoliosis, compression, spurring, degeneration, arthritis, or deformity was labeled. When these “degenerative” patients (n = 23) were compared with osteoporotic patients without degenerative changes (n = 10), there was a significant difference in lumbar T-score (−2.19 ± 0.7 compared with −0.51 ± 1.8, respectively; P <.001). Age, biochemical measurements, ADL scores, and CMI scores did not contribute significantly. There was no seasonal variation in 25-hydroxy vitamin D (not shown).
The illustrates the correlation of hip bone density and spine bone density, as measured by T-score.
In this study, we found that approximately 30% of a sample of men admitted to a VA rehabilitation unit had osteoporosis, and despite being older and thinner than a control group, they had no demonstrable metabolic, functional, or ethnic differences. In a very broad sense, our data are consistent with those of other recent studies. A study of men from the Miami VA nursing home demonstrated that slightly more than 62% had low bone mass (~36% with osteopenia, ~27% with osteoporosis), obesity seemed to correlate with osteoporosis (unlike our study), and ambulatory status did not predict bone mass.11 Although the overall prevalence of osteoporosis in the study by Paniagua et al was comparable to that reported here, their study was unlike ours in other ways11: they used heel densitometry, exclusion criteria were not defined, and demented patients were included and indeed made up a majority of the population. In another study that used heel densitometry as a screening technique, Gloth and Simonson evaluated more than 30,000 skilled nursing facility residents in 26 states; ~42% had T-scores below −2.5. Bedbound patients, those being treated for osteoporosis, and those with a “short life expectancy” were excluded.10 Although these reported prevalence statistics for osteoporosis were comparable to those in our study, our project reported vitamin D, testosterone, TSH, and PTH data, which these earlier reports did not. In a UK study, Aspray et al reported that nursing home residents have an osteoporosis prevalence of 69%; however, the majority of their patients were women.44 A study from New York suggested that elderly men and women admitted to an urban tertiary care hospital with osteoporotic fractures were a heterogeneous group, without clearly consistent predictors.45 In recognition of the enormous morbidity, mortality, and financial impact of osteoporosis, Tucci emphasized the need to screen and treat aggressively to prevent future fractures,46 particularly since osteoporotic fractures in men carry greater morbidity and mortality than those in women.47
Our data provide indirect evidence in support of the need to screen veterans admitted to rehabilitation facilities aggressively, because we were so limited in our ability to identify key factors that might predispose to osteoporosis in men. A randomized controlled trial comparing screening and not screening with respect to fracture outcome might be of value. Similarly, a study demonstrating that treatment prevents fracture in this population would be of interest. It also may be that enough data have accrued in a similar population to allow a modeling study.
Inadequate calcium absorption and vitamin D may contribute to osteoporosis in a nursing home population. Although there was no clear difference in these parameters for patients with and without osteoporosis, both calcium absorption (as measured by 24-hour urine calcium) and circulating vitamin D were at the lower end of normal. Recent studies48 have suggested that the optimal circulating vitamin D concentration is 30 ng/mL or above; both our study populations were well below that level. This may be related to an age-associated decline in skin synthesis49 and appears to transcend age and race distinctions.50 Our assay did not distinguish between 25-hydroxy vitamin D3 and 25-hydroxy vitamin D2. The importance of nutrition may be indicated by our observation that hip bone mass density (T-score) was significantly related to BMI and body weight. Although bone mass is a component of lean body mass, BMI may reflect global nutrition as well as ongoing mechanical bone loading. These findings are distinct from those of Paniagua et al, who reported an increase in osteoporosis in heavier patients,11 suggesting that factors other than BMI alone (eg, activity level) play an important role.
Our assessment of comorbidity, using active diagnoses, ADL scores, and CMI scores, was crude. It may be that more formal instruments such as a Charlson comorbidity scale51 or a functional assessment such as time-to-get-up-and-go52 might provide a better estimate of comorbidity and functional status, and might be a stronger predictor of osteoporosis than the instruments used in our study. In a study of elderly women, strength was positively associated, and BMI was negatively associated, with ADL functional score.53 A study from a rural Japanese community documented that bone loss in both men and women was correlated with decreased ADLs, determined by various reaching and lifting as well as household tasks.54
We found that hip osteoporosis was more common than spine osteoporosis. On the other hand, we also found that a substantial number of our patients with osteoporosis had various degenerative conditions that might artefactually elevate bone density; the actual prevalence of spinal osteoporosis may be underestimated by our data.
It is of interest that there was an apparent improvement in the observed rate of population screening and treatment for osteoporosis in our study population (7% at the onset of the study had been screened for osteoporosis compared with 12% by the end of the study). This improvement may reflect a local idiosyncrasy in evaluation patterns uncovered by the unexpected hiatus in recruitment, as well as a real improvement in provider awareness of osteoporosis and, as a result, screening. On the other hand, other studies have shown a similar poor rate of screening and treatment. Our own group recently reported that only a minority of men who sustained a vertebral fracture were diagnosed with or treated for osteoporosis.55 Feldstein and coworkers reported a very poor rate (<10%) of further evaluation51 after an index fracture in a nationalized healthcare system, where access and cost are not major impediments to care. Other data have showed equally poor rates in other healthcare systems. For example, Rojas-Fernandez and colleagues demonstrated in a nursing home study that only 25% of patients with diagnosed osteoporosis were receiving any antiosteoporosis drugs.56
Our data suggest that men with osteoporosis were older than those without osteoporosis. Although we were not able to document significant metabolic differences between these 2 groups, several explanations are possible. One explanation is that mobility may be impaired in the older men,57 for which we did not adequately screen with our limited functional assessment. Another explanation relates to recent data suggesting that saturated fat intake may be a risk factor; our older veterans may have had a longer exposure to this dietary component.58 Unknown metabolic differences (eg, production of estradiol) also may be factors. Clearly, further study is needed to evaluate this issue.
Age and weight are relative terms. Although we were able to state that in our study population being “older” and “lighter” appeared to predispose men to osteoporosis, we were not able to establish thresholds for these parameters. A substantial number of our admitted patients did not participate in our study, primarily because of their lack of interest and secondarily for reasons pertaining to their ability to adhere to the requirements. It is possible that our data may represent a select population and that those individuals who could not or would not participate were in fact sicker and might have displayed differences in the various metabolic parameters studied. On the other hand, our analysis of a sample of nonparticipants did not reveal significant differences in parameters of overall health such as length of stay, active medical problems, weight, or BMI.
Another limitation to our study is the use of Lunar rather than National Health and Nutrition Examination Survey hip bone mass density reference data. Although the Lunar database was used consistently to evaluate all patients in this study, it may not be as widely representative as the National Health and Nutrition Examination Survey.59
Furthermore, by restricting our analysis to men who had served in active military duty, we might have distorted our data to include individuals who at one time were healthy and in good physical condition. As such, we might in fact underreport the prevalence of osteoporosis in a middle-aged, infirm male population. Patients admitted to the CREC frequently go home and may be more functional than other institutionalized men. Thus, our data represent an analysis of a relatively narrow spectrum of society, and extrapolating to a larger segment could be unfounded. Nonetheless, it is clear that osteoporosis is rarely screened for in an ambulatory population and may be more prevalent than had been appreciated.
The underappreciated prevalence of osteoporosis and the significant potential burden from morbidity in men make it imperative for healthcare providers to evaluate at-risk patients. This situation obviously has huge financial importance for healthcare organizations. Our inability to identify clear distinguishing markers for men at risk—even recognizing the caveats outlined above—suggests that aggressive bone density screening, particularly of frail, thin, or elderly men, may be the most cost-effective intervention at this time.
Nayim Akmal, MD, assisted in early recruitment efforts.
Author Affiliations: From the Veterans Affairs Northern California Health Care System (AS, JAG, GH, CAB, IDM, EBH, MFR, RHN), Martinez, CA; and the Department of Internal Medicine (AS, JAG, GH, RHN), University of California—Davis, Davis, CA.
Funding Source: This research was supported in part by an investigatorinitiated grant from Merck & Co, Inc. The sponsor had no role in the design, methods, subject recruitment, data collection, analysis, or preparation of this article.
Author Disclosures: The authors (AS, JAG, GH, CAB, IDM, EBH, MFR, RHN) report no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this article.
Authorship Information: Concept and design (AS, JAG, RHN); acquisition of data (AS, GH, CAB, IDM, EBH, MFR); analysis and interpretation of data (AS, JAG, GH, CAB, IDM, RHN); drafting of the manuscript (AS); critical revision of the manuscript for important intellectual content (AS, JAG, GH, CAB, IDM, RHN); statistical analysis (AS); provision of study materials or patients (AS, EBH, MFR); obtaining funding (AS); administrative, technical, or logistic support (AS, GH, EBH, MFR); and supervision (AS).
Address correspondence to: Arthur Swislocki, MD, Medical Service (612/111), VANCHCS, 150 Muir Rd, Martinez, CA 94553. E-mail: arthur. firstname.lastname@example.org.
1. Ray NF, Chan JK, Thamer M, Melton LJ 3rd. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12(1):24-35.
2. Reginster JY, Deroisy R, Pirenne H, et al. High prevalence of low femoral bone mineral density in elderly women living in nursing homes or community-dwelling: a plausible role of increased parathyroid hormone secretion. Osteoporosis Int. 1999;9(2):121-128.
3. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med. 1997;103(2A):12S-17S.
4. Kannus P, Parkkari J, Sievänen H, Heinonen A, Vuori I, Järvinen M. Epidemiology of hip fractures. Bone. 1996;18(1 suppl 1):57S-63S.
5. Ebeling PR. Osteoporosis in men. New insights into aetiology, pathogenesis, prevention, and management. Drugs Aging. 1998;13(6): 421-434.
6. Ross PD. Osteoporosis. Frequency, consequences, and risk factors. Arch Intern Med. 1996;156(13):1399-1411.
7. Kurland ES, Rosen CJ, Cosman F, et al. Insulin-like growth factor-I in men with idiopathic osteoporosis. J Clin Endocrinol Metab. 1997; 82(9):2799-2805.
8. Lips P. Epidemiology and predictors of fractures associated with osteoporosis. Am J Med. 1997;103(2A):3S-8S.
9. Nguyen TV, Eisman JA, Kelly PJ, Sambrook PN. Risk factors for osteoporotic fractures in elderly men. Am J Epidemiol. 1996;144(3):255- 263.
10. Gloth FM 3rd, Simonson W. Osteoporosis is underdiagnosed in skilled nursing facilities: a large-scale heel BMD screening study. J Am Med Dir Assoc. 2008;9(3):190-193.
11. Paniagua MA, Malphurs JE, Samos LF. BMI and low bone mass in an elderly male nursing home population. Clin Interv Aging. 2006;1(3):283-287.
12. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest. 1998;102(8):1627-1633.
13. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 1997;337(6):382-387.
14. Picado C, Luengo M. Corticosteroid-induced bone loss. Prevention and management. Drug Saf. 1996;15(5):347-359.
15. Gallego-Rojo FJ, Gonzalez-Calvin JL, Muñoz-Torres M, Mundi JL, Fernandez-Perez R, Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology. 1998;28(3):695-699.
16. Khosla S, Hassoun AA, Baker BK, et al. Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis. Potential insights into increasing bone mass in adults. J Clin Invest. 1998;101(10):2165-2173.
17. Tsuneoka K, Tameda Y, Takase K, Nakano T. Osteodystrophy in patients with chronic hepatitis and liver cirrhosis. J Gastroenterol. 1996;31(5):669-678.
18. Chen CC, Wang SS, Jeng FS, Lee SD. Metabolic bone disease of liver cirrhosis: is it parallel to the clinical severity of cirrhosis? J Gastroenterol Hepatol. 1996;11(5):417-421.
19. Runge M, Schacht R. Proximal femoral fractures in the elderly: pathogenesis, sequelae, interventions [in German]. Rehabilitation. 1999;38(3):160-169.
20. Zimmerman SI, Girman CJ, Buie VC, et al. The prevalence of osteoporosis in nursing home residents. Osteoporosis Int. 1999;9(2):151-157.
21. Evans WJ. Exercise training guidelines for the elderly. Med Sci Sports Exer. 1999;31(1):12-17.
22. Slemenda C. Prevention of hip fractures: risk factor modification. Am J Med. 1997;103(2A):65S-71S.
23. The WHO Study Group. Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis. Geneva: World Health Organization; 1994.
24. Lufkin EG, Wahner HW, O’Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117(1):1-9.
25. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclic etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990;323(2): 73-79.
26. Ohlsson C, Bengtsson BA, Isaksson OG, Slootweg MC. Growth hormone and bone. Endocr Rev. 1998;19(1):55-79.
27. Eastell R, Boyle IT, Compston J, et al. Management of male osteoporosis: report of the UK Consensus Group. QJM. 1998;91(2):71-92.
28. Hannon R, Blumsohn A, Naylor K, Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res. 1998;13(7):1124-1133.
29. Crosbie OM, Freaney R, McKenna MJ, Hegarty JE. Bone density, vitamin D status, and disordered bone remodeling in end-stage chronic liver disease. Calcif Tissue Int. 1999;64(4):295-300.
30. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res. 1998;13(9):1431-1438.
31. Murphy MG, Bach MA, Plotkin D, et al. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK- 677 Study Group. J Bone Miner Res. 1999;14(7):1182-1188.
32. Bauer DC, Sklarin PM, Stone KL, et al. Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures. J Bone Miner Res. 1999;14(8): 1404-1410.
33. Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY Study. J Bone Miner Res. 1999;14(9):1614-1621.
34. Watts NB. Clinical utility of biochemical markers of bone remodeling. Clin Chem. 1999;45(8, pt 2):1359-1368.
35. Braga de Castro Machado A, Hannon R, Eastell R. Monitoring alendronate therapy for osteoporosis. J Bone Miner Res. 1999;14(4):602- 608.
36. Yilmaz N, Bayram M, ErbåË‡g ci AB, Kilinçer MS. Diagnostic value of biochemical markers of bone turnover and postmenopausal osteoporosis. Clin Chem Lab Med. 1999;37(2):137-143.
37. Garnero P, Delmas PD. Biochemical markers of bone turnover. Applications for osteoporosis. Endocr Metab Clin North Am. 1998; 27(2):303-323.
38. de Vernejoul MC. Markers of bone remodelling in metabolic bone disease. Drugs Aging. 1998;12(suppl 1):9-14.
39. Bikle DD. Biochemical markers in the assessment of bone disease. Am J Med. 1997;103(5):427-436.
40. Swislocki A, Barnett CA, Darnell P, Noth RH. Hyperthyroidism: an underappreciated cause of diffuse bone disease. Clin Nucl Med. 1998;23(4):241-243.
41. Centers for Medicare & Medicaid Services. MDS 2.0 public quality indicator and resident reports. Overview. http://www.cms.gov/ MDSPubQIandResRep/. Accessed April 23, 2010.
42. Hodgson SF, Watts NB, Bilezikian JP, et al; AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003 [published correction appears in Endocr Pract. multiple author names added. Endocr Pract. 2004;10(1):90]. Endocr Pract. 2003;9(6):544-564.
43. Dawson-Saunders B, Trapp RG. Basic and Clinical Biostatistics. Norwalk, CT: Appleton and Lange; 1990.
44. Aspray TJ, Stevenson P, Abdy SE, et al. Low bone mineral density measurements in care home residents—a treatable cause of fractures. Age Ageing. 2006;35(1):37-41.
45. Becker C, Crow S, Toman J, et al. Characteristics of elderly patients admitted to an urban tertiary care hospital with osteoporotic fractures: correlations with risk factors, fracture type, gender and ethnicity. Osteoporos Int. 2006;17(3):410-416.
46. Tucci JR. Importance of early diagnosis and treatment of osteoporosis to prevent fractures. Am J Manag Care. 2006;12(7 suppl): S181-S190.
47. Amin S. Male osteoporosis: epidemiology and pathophysiology. Curr Osteoporos Rep. 2003;1(2):71-77.
48. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson- Hughes B. Estimation of optimal serum concentrations of 25- hydroxyvitamin D for multiple health outcomes [published corrections appear in J Clin Nutr. 2006;84(5):1253. Dosage error in published abstract; MEDLINE/PubMed abstract corrected. Am J Clin Nutr. 2007;86(3):809. Dosage error in published abstract; MEDLINE/PubMed abstract corrected]. Am J Clin Nutr. 2006;84:18-28.
49. Heaney RP. Barriers to optimizing vitamin D3 intake for the elderly. J Nutr. 2006;136(4):1123-1125.
50. Dawson-Hughes B. Racial/ethnic considerations in making recommendations for vitamin D for adult and elderly men and women. Am J Clin Nutr. 2004;80(6 suppl):1763S-1766S.
51. Feldstein AC, Nichols G, Orwoll E, et al. The near absence of osteoporosis treatment in older men with fractures. Osteoporos Int. 2005;16(8):953-962.
52. Dukas L, Staehelin HB, Schacht E, Bischoff HA. Better functional mobility in community-dwelling elderly is related to D-hormone serum levels and to daily calcium intake. J Nutr Health Aging. 2005;9(5):347- 351.
53. Davis JW, Ross PD, Preston SD, Nevitt MC, Wasnich RD. Strength, physical activity, and body mass index: relationship to performancebased measures and activities of daily living among older Japanese women in Hawaii. J Am Geriatr Soc. 1998;46(3):274-279.
54. Oka H, Yoshimura N, Kinoshita H, et al. Decreased activities of daily living and associations with bone loss among aged residents in a rural Japanese community: the Miyama Study. J Bone Miner Metab. 2006;24(4):307-313.
55. Nakai Y, Noth R, Wexler J, Volpp B, Tsodikov A, Swislocki A. Computer-based screening of chest x-rays for vertebral compression fractures as an osteoporosis index in men. Bone. 2008;42(6):1214-1218.
56. Rojas-Fernandez CH, Lapane KL, MacKnight C, Howard KA. Undertreatment of osteoporosis in residents of nursing homes: populationbased study with use of the Systematic Assessment of Geriatric drug use via Epidemiology (SAGE) database. Endocr Pract. 2002;8(5):335- 342.
57. Sharma S, Fraser M, Lovell F, Reece A, McLellan AR. Characteristics of males over 50 years who present with a fracture: epidemiology and underlying risk factors. J Bone Joint Surg Br. 2008;90(1):72-77.
58. Melhus H, Risérus U, Warensjö E, et al. A high activity index of stearoyl-CoA desaturase is associated with increased risk of fracture in men. Osteoporos Int. 2008;19(7):929-934.
59. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltaev N. A reference standard for the description of osteoporosis. Bone. 2008;42(3):467-475.